Synopsis: The share jumps 11 % on robust This fall efficiency, pushed by sturdy ANDA (Abbreviated New Drug Utility) pipeline and 385 % development in branded generics, signalling robust future development visibility.
The share of this firm, which is a research-driven firm centered on growing and manufacturing complicated generics, with a robust presence within the US, Canada, and controlled markets, got here into focus after robust This fall section efficiency.
With a market capitalization of Rs 4,831 crore, Senores Prescription drugs Ltd’s shares on Friday made a day excessive of Rs 1,062 per share, up 11.2 % from its earlier day’s shut value of Rs 954.80 per share. The share of this firm gave a damaging return of 94 % over the past yr.
Outcomes Overview
Fiscal yr comparability: Income from operations elevated from Rs 398 crore in FY25 to Rs 633 crore in FY26, up 59 % year-on-year. Revenue earlier than tax rose from Rs 71 crore in FY25 to Rs 159 crore in FY26, a soar of 124 %. Revenue after tax improved from Rs 58 crore in FY25 to Rs 122 crore in FY26, up 110.3 %. Earnings per share elevated from Rs 12.72 in FY25 to Rs 25.02 in FY26, reflecting a development of 97 %.
This fall Enterprise Spotlight
Money stream from operations improved considerably to Rs 75 crore in FY26, indicating a robust turnaround in operational effectivity. Higher EBITDA-to-cash conversion displays tighter working capital administration and improved execution, supporting more healthy liquidity era and strengthening general monetary flexibility for future growth plans.
The regulated markets pipeline stays sturdy with 51 authorized ANDAs overlaying 151 strengths. Moreover, greater than 30 ANDAs are but to be launched, and 27 are beneath improvement throughout 65 plus strengths. This robust pipeline supplies multi-year income visibility and helps sustained development momentum in regulated geographies.
Rising markets continued regular efficiency in FY26 with income development of round 13 % year-on-year and EBITDA margin close to 12 %, supported by a centered product combine. Branded generics delivered distinctive momentum, surging about 385 % year-on-year, pushed by growing acceptance throughout multi-specialty and specialty hospitals, strengthening long-term scalability.
Phase efficiency
- Regulated Markets driving core development by means of ANDA pipeline: Regulated Markets income jumped to Rs 117.8 crore in Q4FY26 from Rs 64.3 crore in Q4FY25, up 83 % YoY. FY26 income stood at Rs 427.4 crore versus Rs 244.8 crore, reflecting robust 74.6 % development, supported by increasing ANDA-led product approvals and launches.
- Robust visibility from increasing product portfolio: Development momentum in regulated markets is backed by a widening ANDA pipeline, which continues to strengthen multi-year income visibility and helps scaling of complicated generic choices in international markets.
- Branded Generics rising as high-growth driver: Branded Generics income surged 132.4 % YoY in Q4FY26 to Rs 9.4 crore and rose sharply by 385.3 % in FY26 to Rs 40 crore versus Rs 8.2 crore, reflecting fast traction and hospital acceptance.
- Diversified segments supporting general sustainability: Rising Markets grew 25.8 % in Q4FY26 and 19.7 % in FY26, whereas complete earnings rose 57.9 % in Q4FY26 to Rs 189.7 crore, indicating balanced development throughout geographies and product segments.
In regards to the Enterprise
Senores Prescription drugs Ltd is an Ahmedabad-based, research-driven pharmaceutical firm integrated in 2017, specializing within the improvement and manufacturing of complicated generics, specialty, and important care injectables. It has a world presence, exporting to 49+ international locations and working 3 manufacturing services (together with USFDA-approved websites) within the USA and India.
Disclaimer: The views and funding ideas expressed by funding consultants/broking homes/ranking businesses on tradebrains.in are their very own, and never that of the web site or its administration. Investing in equities poses a threat of economic losses. Traders should subsequently train due warning whereas investing or buying and selling in shares. Commerce Brains Applied sciences Non-public Restricted or the creator usually are not answerable for any losses prompted because of the choice primarily based on this text. Please seek the advice of your funding advisor earlier than investing.
